Gennova Biopharmaceuticals, a Pune-based pharmaceutical company, has submitted phase 2 trial data of its mRNA COVID-19 vaccine for approval. The Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) is expected to review the data soon.

Gennova Biopharmaceuticals has also completed the recruitment of phase 3 clinical trial data. The pharma company has also developed the mRNA vaccine for the Omicron variant of COVID-19 that will be tested on humans for efficacy & immunogenicity soon.

Read more at https://www.jagranjosh.com/current-affairs/gennova-submits-phase-2-...